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Abstract
Alzheimer’s disease is the most common cause of dementia worldwide, affecting the elderly population. It is characterized
by the hallmark pathology of amyloid-b deposition, neurofibrillary tangle formation, and extensive neuronal degeneration
in the brain. Wealth of data related to Alzheimer’s disease has been generated to date, nevertheless, the molecular
mechanism underlying the etiology and pathophysiology of the disease is still unknown. Here we described a method for
the combined analysis of multiple types of genome-wide data aimed at revealing convergent evidence interest that would
not be captured by a standard molecular approach. Lists of Alzheimer-related genes (seed genes) were obtained from
different sets of data on gene expression, SNPs, and molecular targets of drugs. Network analysis was applied for identifying
the regions of the human protein-protein interaction network showing a significant enrichment in seed genes, and
ultimately, in genes associated to Alzheimer’s disease, due to the cumulative effect of different combinations of the starting
data sets. The functional properties of these enriched modules were characterized, effectively considering the role of both
Alzheimer-related seed genes and genes that closely interact with them. This approach allowed us to present evidence in
favor of one of the competing theories about AD underlying processes, specifically evidence supporting a predominant role
of metabolism-associated biological process terms, including autophagy, insulin and fatty acid metabolic processes in
Alzheimer, with a focus on AMP-activated protein kinase. This central regulator of cellular energy homeostasis regulates a
series of brain functions altered in Alzheimer’s disease and could link genetic perturbation with neuronal transmission and
energy regulation, representing a potential candidate to be targeted by therapy.
Citation: Caberlotto L, Lauria M, Nguyen T-P, Scotti M (2013) The Central Role of AMP-Kinase and Energy Homeostasis Impairment in Alzheimer’s Disease: A
Multifactor Network Analysis. PLoS ONE 8(11): e78919. doi:10.1371/journal.pone.0078919
Editor: Peter Csermely, Semmelweis University, Hungary
Received July 18, 2013; Accepted September 23, 2013; Published November 12, 2013
Copyright: ! 2013 Caberlotto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: caberlotto@cosbi.eu
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized neuropathologically by the extracellular accumula-
tion of amyloid-beta plaques and the intracellular accumulation of
hyperphosphorylated tau protein, the neurofibrillary tangles [1].
AD is the most prevalent neurodegenerative disorder worldwide
and it is a complex disease associated with multiple genes [2].
Although a large body of literature focuses on the importance of a
few key proteins for AD onset and progression, our understanding
of the etiopathology of the disease is still very limited. Current
medical treatments for AD are purely symptomatic and hardly
effective [3], thus, the understanding of the molecular mechanisms
underlying AD is essential for the development of novel therapies.
Over the last decade, many studies have been devoted to
dissecting the molecular pathways involved in AD using a variety
of experimental designs and technological approaches, including
genomic-wide linkage scans [4], genetic association studies [5],
and microarray gene expression investigations [6–11]. In the
present study, a systems biology approach was applied to extract
overlapping evidence from different sources of AD-related data.
Our convergent analysis of different data types enabled us to
overcome the limitation of analyzing each single data type in
isolation and to provide a multi-source, unbiased view of the
evidence embedded in the genomic, transcriptomic, and drug
molecular targets. As a final step, Alzheimer’s disease associated
genes and genetic phenotypes collected in the Online Mendelian
Inheritance in Man (OMIM) database representing the consoli-
dated knowledge on AD were integrated in the analysis to validate
the method. Previous computational studies have tried to integrate
different text mining approaches, genetic, functional or -omics
data to provide hypotheses for the biological mechanisms
underlying the pathology [12–15]. This is the first attempt to
integrate the genomic aspect of AD with the gene expression and
drug candidate targets. We have used AD-related data obtained
from multiple sources: (1) transcriptomic data of six different post
mortem brain regions of AD affected subjects [11], analyzed using
a newly developed analytical method [16], (2) single nucleotide
polymorphism (SNP) data integrated from multiple studies [17],
(3) molecular targets of Alzheimer’s drugs in the different phases of
the drug discovery process, and, for the validation step, (4) genes
associated to Alzheimer’s disease extracted from the Online
Mendelian Inheritance in Man (OMIM) database [18]. These sets
of data were used to derive lists of seed genes and represented the
basis to perform network analysis. We then used a protein-protein
interaction (PPI) network as a scaffold on which to embed the lists
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of seed genes, with the lists considered both separately and in
different combinations.
A number of methods have been proposed for integrating
experimental data and prior knowledge in the form of PPI
interactions. Some of the existing tools implement network
building methods whose starting point is a list of genes, which
are then used as a backbone for the iterative assembling of
connected networks [19]. Others, such as in Komurov et al. [20],
start considering the whole network structure and then proceed to
assign weighs to nodes to reflect the levels of gene expression from
microarray data. In the present paper, we have developed an
intermediate approach. We have used the whole interaction
network from HPRD [21], partitioned it into modules and tested
their enrichment in terms of seed genes. We have, then, character-
ized the biological properties of the significantly enriched reference
modules by studying the over-represented GO biological process
(GOBP) terms (Figure 1). Our method combines the merits of the
holistic perspective considering the whole network structure,
allowing the concurrent comparison of different data types.
This biomolecular network has provided a richer setting to
characterize genes found to be involved in AD and to identify
AMP-activated protein kinase (AMPK) signaling, a metabolic
sensoring pathway and energy regulators including neuropeptides,
as a major player in the pathophysiology of AD, which could
explain various aspects of AD pathogenesis.
Materials and Methods
Seed Genes Lists
The lists of seed genes (1) extracted from gene expression data, (2)
identified with significant SNPs, (3) obtained after data search for
drug targets, and (4) retrieved from OMIM database were
obtained as described in the following, and are reported in Tables
S1.
Gene expression seed genes. Microarray data were down-
loaded from Gene Expression Omnibus (GEO; http://www.ncbi.
nlm.nih.gov/geo/). Dataset GSE5281 [11] refers to a series of
brain regions differentially affected by Alzheimer’s disease and was
selected based on the good quality of the experimental design. Full
description of the dataset is reported in [11]; briefly, histologically
non-affected neurons were collected by laser-capture microdissec-
tion from six different brain regions: entorhinal cortex (EC),
hippocampus (HIP), medial temporal gyrus (MTG), posterior
cingulate cortex (PC), visual cortex (VCX), and superior frontal
gyrus (SFG). The study population consisted of 11–13 elderly
controls and 10–23 AD affected subjects for each region. The pre-
processed version of dataset GSE5281 was downloaded and used
without modifications. In order to derive lists of relevant genes, we
first obtained AD differential expression profiles by dividing each
AD profile by the average of the controls for the respective region
(i.e., the HIP profiles in AD patients by the average of HIP profiles
in controls). We then ranked each profile separately, from the most
expressed to the least expressed probeset; at the end of this step,
each probeset had a separate rank assigned to it for each of the
expression profiles. In order to obtain a brain region-specific
ranked probeset list, we summed the ranks for each region
separately, and then we re-ranked the probesets according to the
rank sums. Finally, the top 125 and the bottom 125 probesets were
collected for each region, to form a brain region-specific list. The
value of the length of these lists (125+125) was selected as the one
that gave the best partitioning of the map of samples in well-
defined groups, thus corresponding to a maximally informative
and minimally redundant expression signature. We have shown
that the signature length is not critical, in the sense that usually the
Figure 1. Schematic representation of the network analysis workflow. Significant gene expression signatures associated to AD were
extracted from the GSE5281 dataset, while lists of SNPs, drug targets, and OMIM Alzheimer’s genes were obtained from public databases. These seed
genes (in yellow and orange) inform about transcriptomic and genetic properties of AD, also providing details on drug targets in the different phases
of the drug discovery process and AD associated genes in the OMIM database. Following module structure detection in the protein-protein
interaction (PPI) network derived from HPRD data (see groups of nodes in the same white-background circles), we investigated the presence of
reference modules where seed genes (obtained through the three simple lists and their union) were over-represented. We characterized the
functionality of these enriched modules by testing over-represented Gene Ontology biological process terms, both considering seed genes (in yellow
and orange) and non-seed genes (in light blue) that closely interact with them.
doi:10.1371/journal.pone.0078919.g001
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range of values resulting in a satisfactory clustering of the map is
quite wide [16,22].
The map was obtained by measuring the reciprocal distance
between the lists extracted from each profile, and then represent-
ing such distances in the form of a graph (Figure S1), as detailed
elsewhere [16].
SNPs seed genes. SNPs data were obtained from the
AlzGene database (www.alzgene.org). Only highly significant
meta-analysis results (p-values ,0.00001) were used to select a
subset of SNPs – AD-associated genes confirmed by numerous
studies [17]. We tested separately the complete dataset (533 SNPs)
as well for the additional statistical analysis.
Drug targets seed genes. Drug molecular targets were
obtained by collecting information from different pharmaceutical
company websites and from a clinical trial database (www.
clinicaltrials.gov). Drugs in all phases of the drug discovery
process, from preclinical to marketed drugs, were included. This
allowed obtaining the broadest coverage of the genes of interest for
pharmaceutical drug development to identify the overall key
molecular targets of interest for the treatment of AD. Only
primary targets were considered as seed genes for network analysis.
OMIM seed genes. Alzheimer’s disease genes and genetic
phenotypes were extracted from the OMIM database, using
Alzheimer’s disease as reference keyword [18].
Network Construction and Analysis
For protein interaction data, we used the 2009 version of the
Human Protein Reference Database (HPRD; http://www.hprd.
org/). This is a literature-curated human PPI interaction network
comprising 37039 interactions among 9617 genes [21]. Nodes of
the network are the genes (named with gene symbols), while edges
stand for protein-protein interactions (e.g., enzymatic, regulatory,
transcriptional). We removed loops (edges for which the two
endpoints are the same gene) and duplicate edges (interactions
with the same two nodes that are listed more than once), and
identified the maximal connected component of the network (giant
component). The final network was composed of 9219 genes and
36900 interactions. To find network modules, we analyzed the
final network with the ‘‘spinglass.community’’ function [23]
included in the R package igraph [24]. Network modules represent
cohesive subgroups composed of genes that are more intimately
interconnected among each other than with the rest of the
network. Using the ‘‘spinglass.community’’ function, these mod-
ules are identified only considering the arrangements of network
interactions. Since the module detection function maximizes the
modularity by adopting a heuristic approach, module structure
(i.e., number, size and node composition) might slightly change in
different runs [23,25]. To deal with this, we ran the ‘‘spinglass.-
community’’ partitioning algorithm 100 times. At each run, we
performed hypergeometric tests (p-values threshold 0.05) using the
‘‘multiHyperGeoTest’’ function from the R package HTSanaly-
zeR [26] to identify the network modules that were significantly
enriched with seed genes considered for that run (differentially
expressed genes, SNPs, drug targets, OMIM genes or lists
obtained from their union). When more enriched modules were
found, we compared their size and composition to identify the
substantially overlapping modules across multiple runs (Figure S2).
First, we grouped enriched modules based on their size, applying
the function ‘‘hist’’ of the R package graphics (and using the
option: breaks = "Sturges"; see [27]). The composition of signifi-
cant modules of similar size was compared and eventually merged
into a new reference module summarizing the results of multiple
runs (i.e., in case this did not alter significant statistics on gene
enrichment). Each reference module was obtained by selecting the
largest number of genes and interactions found with different runs.
To avoid excluding genes and interactions of possible interest, we
considered the largest amount of genes and interactions as
representative of each reference module, when this did not
compromise the statistics for over-represented seed genes. If the
significant enrichment with seed genes vanished after the union of
more modules, they were considered as representative of different
communities and analyzed as separate sub-networks. The highest
variability was observed for the changes in the number of
interactions while module composition was more stable during
different runs. We also required all reference modules to be
constituted by sets of connected nodes. Once the composition of
these reference modules was identified, we used the whole lists of
‘‘reference module genes’’ to extract the most representative GO
biological process terms (i.e., the ones that are over-represented,
but that do not refer to most general biological processes). For
identifying and visualizing enriched GO terms, we used GOrilla
and REVIGO tools; hypergeometric distribution was applied to
test GO term enrichment, and a p-value threshold of 0.001 was
selected [28,29].
Statistical Analyses on the Relatedness of AMPK to AD
In order to characterize the relevance of AMPK system in AD a
series of three types of statistical analysis was performed. AMPK is
represented in the final network by 9 nodes: 2 protein kinase,
AMP-activated, catalytic subunits (i.e., PRKAA1, PRKAA2); 5
protein kinase, AMP-activated, non-catalytic subunits (i.e,
PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3), the
acetyl-CoA carboxylase alpha (ACACA) and beta (ACACB).
They result in a sub-network of 9 nodes collectively called ‘‘AMPK
nodes’’. These nodes are surrounded, in the final network, by 25
direct neighbors. Altogether, they result in a sub-network of 34
‘‘AMPK nodes+neighbors’’.
First, we measured the frequency of the 9 AMPK nodes and 34
‘‘AMPK nodes+neighbors’’ in the enriched modules. We applied
the Shapiro-Wilk test (function ‘‘shapiro.test’’ from the R package
nortest) to assess the normality of the count distributions for
AMPK and non-AMPK nodes. We used the Wilcoxon rank sum
test (function ‘‘wilcox.exact’’ from the R package exactRankTests)
to investigate whether, in reference modules, AMPK nodes were
characterized by significantly higher frequencies than non-AMPK
nodes.
Second, we checked whether the sub-network of 34 ‘‘AMPK
nodes+neighbors’’ was significantly enriched with seed genes of
different origin, considering first the lists of seed genes separately
and, then, their union. Enrichment was evaluated with the
hypergeometric test and p-values were adjusted with the
Benjamini and Hochberg correction [30].
Third, we measured average and global patterns of shortest
distances linking the 34 ‘‘AMPK nodes and neighbors’’ to seed
genes, and compared their distributions to 1000 subsets obtained by
randomly sampling 34 non-seed and non-AMPK nodes from the
final network using the Wilcoxon signed rank test, following
evaluation of normality of the distributions with the Shapiro-Wilk
test. Comparisons were carried out using both 34 average shortest
paths (‘‘avg’’ scenario) and considering the whole distribution of
shortest paths to seed genes (‘‘all’’ scenario). For each comparison,
we combined the 1000 p-values into a unique p-value by
considering that p-values should be uniformly distributed when
the null hypothesis is true (i.e., when there are no differences
between the distributions of shortest paths obtained with AMPK
and non-AMPK nodes) [31].
In presence of n random uniform variables, the cumulative
distribution function is as follows:
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The left-hand side stands for the probability that the random
variable X takes on a value less than or equal to x; given the k-th
element, the expression (x – k) indicates the positive part of (x – k):
it equals (x – k) if (x – k) is positive and equals 0 otherwise. Due to
the central limit theorem [32], as the number of random uniforms
increases, the sum will converge to a normal distribution with
mean n/2 and variance n/12. This convergence can be used to
estimate a combined p-value for each set of 1000 p-values. If the p-
values are lower than expected from the null, the sum would show
up in the lower tail of the distribution.
Results
We carried out functional enrichment analyses of GO biological
process terms for the reference modules representing unique
network communities characterized by over-represented seed genes.
These modules were determined for each seed genes list separately
(i.e., gene expression, SNPs, drug targets, and OMIM genes) and
then by considering (1) the union of gene expression and SNPs, (2)
the union of gene expression, SNPs, and drug targets, and (3) the
union of gene expression, SNPs, drug targets, and OMIM genes
(Figure 2). After analyzing gene expression data, several reference
modules were found for all brain regions and their number ranged
across the regions, with SFG having the highest number of
reference modules and VCX the lowest. An enriched reference
module was also found associated to drug targets, numerous
modules to OMIM genes associated to Alzheimer’s disease, while
none linked to SNPs (Tables S1). The number of genes per
reference module ranged from 13 to 1885.
Integrating the most significant SNPs with expression data,
enriched reference modules were identified only for four brain
regions: HIP, PC, SFG, and MTG. Adding drug targets to the
analysis, we found enriched communities only in three brain
regions: PC, MTG and SFG, while including in the analysis
OMIM genes five brain regions (PC, MTG, HIP, VCX, and SFG)
were associated to enriched modules (Figure 2).
Complete lists of genes in the enriched modules are summarized
in Tables S1.
Figure 2. Summary of statistically significant Gene Ontology biological processes functional annotation corresponding to genes in
enriched reference modules. Data refers to reference modules obtained using gene expression only (expression), by integrating this information
with SNPs (expression+SNPs), and by merging the mRNA expression data, SNPs and drug targets (expression+SNPs+drug targets), and by combining
the mRNA expression data, SNPs, drug targets, and OMIM genes (expression +SNPs+drug targets+ OMIM). In light blue are GO terms associated to
synaptic transmission and neuronal signaling, in dark green are metabolism-associated GO terms, in gray remaining relevant terms. Highlighted are
the results which have been discussed in detail in the discussion section. Specific GO terms are described in Table S2.
doi:10.1371/journal.pone.0078919.g002
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Table 1 and Figures 2–3 describe the functional annotation
analysis results. Overall, reference modules related to expression
data only in HIP and PC cortical area were mainly related to
metabolism, while in neocortical regions such as MTG and SFG,
both metabolic and higher brain biological process terms related
to neuronal transmission (e.g., neuropeptide, NOTCH, and
synaptic transmission) were represented. Integrating the SNPs
and drug targets data to the expression analysis, PC maintained
the ‘‘metabolic’’-related profile, while in SFG, beside the fact that
the neuronal transmission biological function annotation was
retained, additional GO terms associated with metabolism were
included (Figures 2–3). Including OMIM data in the analysis, a
role for circadian rhythm was evident in the five brain regions (PC,
HIP, SFG, MTG, and VCX). A metabolic profile was still
associated to PC and HIP, SFG and MTG were related to both
metabolic and higher brain functions activities, while VCX was
associated to synaptic transmission. The complete list of specific
GO terms can be found in Table S2.
Comparing the gene lists associated to the groups of similar GO
terms among different brain regions and using different subsets of
data, in most cases there was a good overlap (e.g., Fatty acid and
TOR), while in a few other cases they resulted very different
(Table 1).
Through GO enrichment analysis, we found that AMP-kinase
signaling pathway plays a central role in AD. To further
corroborate this outcome, we tested the statistical relevance of
AMPK-related nodes to AD. We observed that the frequency of
both 9 AMPK nodes and 34 AMPK-related nodes was
significantly higher than the frequency of non-AMPK nodes, in
case of enriched reference modules obtained from the union of
gene expression, SNPs and drug targets. The sub-network of 9
AMPK nodes and their 25 direct neighbors was significantly
enriched with different types of seed genes, especially when
considering the extended list of 533 SNPs. In general, SNPs were
significantly over-represented in the surrounding of AMPK. The
34 AMPK-related nodes showed shorter distances to whole SNPs,
drug targets and OMIM genes in HPRD, if compared to other
non-AMPK and non-seed genes. Results on the AMPK relatedness
to AD are summarized in the Table S3.
We have then investigated whether the reference modules
identified with lists of seed genes, obtained using gene expression
profiles, SNPs, and drug targets, were significantly enriched with
OMIM genes (p-values were estimated with hypergeometric tests -
see the Benjamini & Hochberg correction; adjusted p-value
threshold = 0.1). Results confirmed the outstanding importance
of SFG (altogether, 11 OMIM genes out of the 13 found in HPRD
were included):
– 3 SFG modules (expression data only) were enriched with
OMIM genes (i.e., these 9 genes: PSEN2, BLMH, PSEN1,
PLAU, APOE, APP, HFE, MPO, A2M).
– 2 SFG modules (expression data & SNPs) were enriched with
OMIM genes (i.e., these 8 genes: PSEN2, PSEN1, PLAU,
APOE, APP, HFE, MPO, A2M).
– 2 SFG modules (expression, SNPs & drug targets) were
enriched with OMIM genes (i.e., these 5 genes: PSEN2,
BLMH, PSEN1, NOS3, ACE).
Discussion
The novelty of our investigation is in the approach we used in
integrating multiple data types in order to elucidate the
etiopathology of AD. Our approach can be described as follows.
We sought to combine three different types of data specifically
selected for their potential to shed light on the molecular details of
AD: transcriptomic data in the form of expression profiles in brain,
genetic data in the form of SNPs, and affected pathways in the
form of drug targets.
The starting point of our analysis was a PPI network (data
extracted from the HPRD dataset), which we used as a scaffold to
merge the information derived from the three sets of data. We
applied network analysis for extracting the hints on AD-specific
mechanisms contributed by these three datasets and for revealing
possible overlaps in the biological process terms they refer to. A
preliminary module analysis of the PPI network was performed, a
module being a group of nodes (proteins) characterized by a higher
degree of connectivity to other members of the group than to non-
group nodes, assuming that genes with a highest number of
Table 1. Gene lists associated to main classes of Gene Ontology biological process terms.

























ACACA ACACA PRKAG2 PRKAG3 PRKAA1 PRKAA1 ATG4A PRKAA1 PFG PRKAG1 CRH PRKAA1
ACACB ACACB PRKAB2 PRKAB3 PRKAA2 PRKAA2 ATG10 PRKAA2 PDX1 PRKAG2 ADA PRKAA2
PRKAA1 PRKAA1 ACAB ACAB ATG7 FFAR1 PRKAB1 ADORA1
PRKAA2 PRKAA2 PRKAA2 PRKAA3 MAP1LC3B ANXA1 PRKAB2 GHRL
PRKAB1 PRKAB1 ATG5 NEUROD1 PRKAA1 DRD2
PRKAB2 PRKAB2 GABARAP MC4R PRKAG3
PRKAG1 PRKAG1 NBR1 CAMK2G PRKAA2
PRKAG2 PRKAG2 ATG4B FKBP1B
PRKAG3 PRKAG3 GABARAPL2 MAFA
CACNA1C
Comparative gene lists associated to main classes of Gene Ontology biological process terms derived by integrating gene expression, SNPs and drug targets data in SFG
and PC. In few cases (Fatty acid and TOR signaling) the gene list are perfectly matching, while in Insulin, Autophagy and Circadian Rhythm, they differed considerably.
Seed genes are in bold.
PRKAA1-2, PRKAB1-2 and PRKAG1-3 are AMPK subunits, while ACACA and ACACB are ACC.
doi:10.1371/journal.pone.0078919.t001
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structural connections are also better candidates for more intense
patterns of functional interactions. The aim was finding AD-
pertinent enriched modules (i.e., modules showing a significant
over-enrichment of AD-related genes) in the human PPI
interaction network, for characterizing the most relevant biological
processes associated to these reference modules. We introduced a
novel approach for estimating reference module composition
applying a heuristic algorithm for the concurrent analysis of
heterogeneous experimental data [23]. We avoided overweighting
the importance of a specific data type and, given this choice, we
were unable to utilize an exact method which requires the
integration of network structure with additional properties
concerning nodes and edges, an otherwise excellent solution in
case of mono-dimensional experimental data [20,33]. Other
studies consider the complete network structure for identifying
disease genes [34] or performing functional analyses of genomic
data [20]. However, the most prevalent software tools (e.g.,
GeneGO and Ingenuity Pathway Analysis) adopt list-based
network building methods (i.e., they construct ad-hoc networks
through an iterative process, by including neighbors of seed genes up
to a given distance), or score pre-defined pathways and functional
terms that are over-represented by lists of seed genes [35,36]. Since
our approach combines holistic view (i.e., it uses the whole
network structure) and module detection of an unweighted
network (i.e., it estimates module composition with a heuristic
algorithm, by ranking at the same level all of the experimental data
types) we argue that it is especially suitable for integrating multiple
data types.
The additive role of the data types can be best appreciated by
looking at the significance analysis of AMPK for one, two, three or
four datasets. Table S3.2 (in Table S3) shows that none of the four
data sets is by itself sufficient to identify AMPK, and instead the
use of all three supporting sets (transcriptional, SNP, drug targets)
is necessary for its identification. The addition of OMIM, which
represents the consolidated knowledge on AD and does not
include AMPK (Table S3.1, in Table S3), has the effect of diluting
the supporting evidence for new genes in favor of established ones,
and brings the significance of AMPK below threshold.
The functional properties of the areas of the network enriched
in terms of the three sets of AD-genes (expression, SNPs, and drug
targets) were characterized and revealed that, in posterior
cingulate cortex, the metabolism-related terms display greatest
importance, with particular relevance of insulin, fatty acids and
mitochondrial functions (Figures 2–3). Posterior cingulate cortex is
metabolically affected in the early phases of AD [37] and genes
influencing mitochondrial energy metabolism were found to be
down-regulated in AD patients [10]. However, the subset of genes
identified by Liang and colleagues refers to a great proportion of
the nuclear genes encoding mitochondrial ETC (electron transport
chain) subunits in PC, including TIMMs and TOMMs, which are
required for the transmembrane mitochrondrial transportation of
ETC components, thus differing from the genes highlighted by our
study (Table 1). The genes associated to metabolism-related GO
terms (fatty acid, insulin, mitochondria, mTOR signaling) in PC
have as common and central molecules different subunits of AMP-
activated protein kinase (AMPK; PRKAA1-3, PRKAB1-3;
PRKAG1-3) and AMPK enzyme complex ACC (ACACA,
ACACB). AMPK is a cellular complex involved in intracellular
energy metabolism, a regulator of energy homeostasis. Interest-
ingly, analyzing the enriched modules of drug targets and gene
expression data separately, the same genes were found, with a
convergence to AMPK signaling using data of very different origin
(Tables S1). This energy-sensing enzyme is linked to different
molecular functions that are altered in AD such as defects in
glucose uptake [38], mitochondrial dysfunctions [39] and alter-
ation of autophagy pathways [40]. Recent studies suggest a role for
AMPK in modulation of tau protein phosphorylation and
amyloidogenesis, the major hallmarks of AD. Latest research
indicated an upstream role for AMPK pathway as a critical
mediator of the synaptotoxic effects of amyloid beta [41]. Thus, it
is possible that the altered functionality of AMPK system in AD
patients contributes to a neuronal imbalance in handling energy
Figure 3. Schematic graphs of over-represented Gene Ontology biological process terms in enriched SFG and PC reference
modules. Seed genes were obtained from the union of differentially expressed genes with most significant SNPs and primary drug targets. GO terms
are represented as nodes, and the strongest GO term pairwise similarities are designated as edges in the graph. GO terms are grouped to illustrate
the main metabolic signature in PC, while both metabolic and synaptic transmission functions characterize SFG.
doi:10.1371/journal.pone.0078919.g003
Network Analysis in Alzheimer’s Disease
PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e78919
requirements, leading to higher Ab and phospho-tau. AMPK is
also involved in transmitting energy-dependent signals to the
mammalian clock, thus regulating circadian rhythm; circadian
rhythm disturbances have been well documented in AD as being
part of the disease process, or a reflection of it [42]. The
involvement of AMPK is further corroborated by previous
transcriptome studies in AD post mortem brains where AMPK-
related genes were found to be altered in prefrontal cortex of
affected individuals, with a subunit-specific effect [7]. Also tacrine,
an acethylcholinesterase inhibitor widely used for the treatment of
AD, was shown to induce up-regulation of AMPK subunits in an
in vitro model (E-MTAB-798 in expression ATLAS http://www.
ebi.ac.uk/gxa/) [43]. Further evidence of the central role of
AMPK in AD originates from preclinical and clinical studies. In an
animal model of AD, the triple transgenic mouse model,
pioglitazone treatment, an AMPK activator, results in the
reduction of amyloid plaque, reduced inflammation and reversal
of disease-related behavioral impairment [44]. In a recent clinical
trial, rosiglitazone, an anti-diabetic drug acting on AMPK, was
associated with improved cognition and memory in patients with
mild to moderate AD [45].
In order to associate AMPK functions to genetic alteration in
AD, we investigated the molecular interactions between SNPs and
AMPK-related genes found in the AD enriched modules. We
found that three out of ten SNPs-associated genes in the lists of the
most significant SNPs have a direct relation to AMPK: a genetic
interaction for (1) CLU with ACC (ACACA) and (2) PICALM
with AMPK (PRKAA1/PRKAG2) [46], and co-expression for (3)
CD2AP with AMPK (PRKAB1) [47] (Figure 4). Also CD33,
another gene characterized by a polymorphism that is significantly
associated to AD, is related to AMPK, although indirectly,
through leptin (Figure 4), another key player in energy regulation
whose effects in inhibiting amyloid b production and tau
phosphorylation are dependent on activation of AMPK [48].
Statistical analysis demonstrates also the closeness of AMPK-
related genes to SNPs in comparison to other nodes in the
network. This finding could provide evidence on the functional
role of these loci in the mis-modulation of energy homeostasis, a
scenario that assigns to energy impairment important roles in
predisposing the brain to the etiology and pathogenesis of this
condition.
The advocated role of AMPK and direct neighbor genes in AD
was also supported by statistical analyses. Different lists of seed genes
that are relevant for AD were overrepresented in the sub-network
composed of AMPK genes and their direct neighbors. In addition,
AMPK-related nodes showed significantly shorter distances to
Figure 4. Simplified schematic graph of AMPK interactions with. (1) genes included in the enriched reference modules (purple), (2)
differentially expressed genes (pink), (3) drug targets (light blue), and (4) SNPs (orange). Ellipses show the biological process terms associated to the
genes (color as in Figure 2) and altered in AD; rhomboid shapes stand for histological markers of AD.
doi:10.1371/journal.pone.0078919.g004
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SNPs, drug targets and OMIM genes in comparison to randomly
chosen nodes from the network.
Recently, a specific Alzheimer’s network was proposed by
Mizuno and colleagues [49], a catalogue mapping of AD signaling
pathway based on literature mining. Thus, we tried to merge this
AD network with the enriched reference module (obtained from
the integration of the three datasets). Among the few overlapping
genes (ULK1, INPP5K, CIB1, PRKG1, SR1, ADRBK1, GNAQ,
UBE2M, PCSK1, PRKAA2) an AMPK subunit, PRKAA2, was
found, further emphasizing the relevant role of AMPK in AD.
In superior frontal gyrus, the functional categories that are over-
represented in significantly enriched reference modules converge
not only to metabolic functions as in posterior cingulate cortex, but
also to synaptic transmission. They comprise numerous neuro-
transmitter signaling pathways, including dopaminergic, GABAer-
gic, glutamatergic, serotonergic, and neuropeptidergic systems
(Figure 3). Altered cognition, learning and memory are clinical
major features of AD and well known is the role of all major
neurotransmitters in this higher brain function in physiological
conditions and in AD [50]. Our findings give also support for a
role of neuropeptidergic transmission in AD, in particular
orexigenic neuropeptides (neuropeptide Y, orexin, agouti-related
peptide, proopriomelnocortin, dynorphin, neuropeptide FF) that
are involved in food intake and energy regulation. This advocates
for a potential association to alteration of energy homeostasis in
AD and AMPK, as this latter has been shown to mediate the
orexigenic or anorexigenic effects of various neuropeptide signals
[51]. AMPK appears also to couple energy metabolism to
neuronal plasticity, as suggested by [52], thus linking energetic
deficiency to alteration in synaptic transmission and memory
impairment. This may possibly explain how memory could be
controlled by energy metabolism, organization of the cytoskeleton
and other biological processes relevant for neuronal survival.
The validity of the result were also tested using OMIM AD-
related genes by adopting two strategies: OMIM genes were used
(1) as a control, by checking their presence in reference modules
found using the three original lists of seed genes, or (2) as a fourth list
of seed genes and treated as an additional layer of evidence. In the
first strategy, the significant enrichment of OMIM Alzheimer’s
disease associated genes found in previously identified reference
modules strengthens the conclusions of the three-level analysis. In
the context of the second strategy, when used as an additional
layer of evidence, the results did not perturb the findings for PC
and SFG (Figure 2), thus confirming the robustness of our
methodological approach to the addition of a new set of
independent data.
Additionally, the presence of AMPK-related genes in this new
set of reference modules passed two out of three of our significance
tests. The additional enriched modules contributed by the OMIM
seed genes list were biased in favor of well-known AD genes, and as a
result AMPK-related genes did not reach significance threshold
when tested for frequency in reference modules. Thus the negative
outcome of the test simply reflects the fact that the addition of a list
of known AD genes to the analysis has the effect of diluting the
significance of newly discovered genes such as AMPK.
Conclusions
In the present study, a novel multifactorial network analysis
approach provided evidence, together with a number of recently
published findings [53–55], suggesting that the deregulation of
various metabolic factors and energy homeostasis, possibly
determined by aging process, play a key role in AD. These
processes possibly involve orexigenic neuropeptides and, particu-
larly, AMPK. These alterations, in an adverse genetic environ-
ment, could explain the major hallmark of AD, tangle and
plaques, all the modifications in metabolic signaling and cognitive
functions, and the inflammatory and apoptotic events seen in AD.
We hypothesize that these processes could be activated by the
conflict between the low level of energy metabolism and the high
level of regulatory and repair load, as suggested by Sun and
colleagues [10]. Future studies will focus on the specific
investigation of these metabolic alterations also on a systemic
level, with the inclusion in the analysis of studies in blood samples
from affected individual.
Supporting Information
Figure S1 Map of the gene expression signature of the
samples from the GSE5281 dataset. Each node represents a
sample, and an edge between two nodes represents the distance
between the respective transcriptional signatures. The spontaneous
clustering of the samples in groups reflects the existence of classes
of highly similar expression profiles corresponding almost perfectly
to the tissue of origin (color legend: EC=orange, MTG= red,
SFG= cyan, HIP= purple, VCX=yellow, PC=blue). The map
was obtained with a signature size of 125+125 genes (up-
regulated+down-regulated); only the top 20% of all pairwise
distances were included in the map as edges.
(TIF)
Figure S2 Schematic representation illustrating the
procedure for identifying reference modules. We use the
giant component of HPRD to detect modules that are significantly
enriched with respect to different lists of seed genes. Consider a
hypothetical case with seed genes overrepresented in 10 modules,
after running 100 times the ‘‘spinglass.community’’ algorithm. To
understand possible redundancies (i.e., the fact that the same
module is found during different runs), we have to compare size
and composition of significantly enriched modules. First, enriched
modules are classified on the basis of their size (e.g., in this
hypothetical example, the 10 enriched modules are classified in
four size categories: (a) 9, 9; (b) 80, 76 and 82; (c) 200, 480, 520
and 512; (d) 1023). If we focus on the first group, two enriched
modules of size 9 are included. After classifying these two modules
in the same size group, we have to determine whether they can be
merged (i.e., they have to share some nodes and interactions so
that seed gene enrichment found with constitutive modules is still
significant after their union). At this step, there can be three
possible scenarios: (1) the modules can be successfully merged,
without altering the significance of the statistics (i.e., there are 4
seed genes out of 10 in the new reference module); (2) the modules
share some nodes and connections, but after their merging the
significant enrichment in seed genes vanishes (i.e., there are 3 seed
genes out of 16, and the two initial modules should be considered as
separate reference modules); (3) the two initial modules do not
share any node (and connection), and have to be considered as
representative of two different reference modules (where seed genes
are significantly enriched with the following ratios: 3/9 and 4/9).
(EPS)
Table S1 This file includes seed genes extracted from
expression data of AD patients, SNPs that are signifi-
cantly associated to AD, AD primary drug targets, and
AD OMIM genes. The remaining spreadsheets show the lists of
genes composing enriched reference modules in AD-related data.
They refer to reference modules detected using the differentially
expressed genes, drug targets and OMIM genes alone (no enriched
modules were found with SNPs), but also describe the composition
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of reference modules where genes from (1) the union of
transcriptomic and genetic signatures, (2) the union of genes
identified with transcriptomic, genetic and drug target, and (3) the
union of transcriptomic, genetic, drug targets and OMIM genes
data are over-represented.
(XLSX)
Table S2 Summary of the specific GO terms corre-
sponding to the main classes listed in Figures 2–3.
(XLSX)
Tables S3 Statistical analysis of the relatedness of
AMPK signaling to AD. (1) Frequency of AMPK nodes in
the enriched reference modules, (2) Enrichment analysis specific to
AMPK nodes and their direct neighbors, (3) Shortest distances
linking AMPK nodes to seed genes.
(DOCX)
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